Mometasone Target (Mometasone Furoate)

Mometasone furoate acts as an agonist at glucocorticoid receptors in nasal tissues. By binding these receptors, it alters gene expression to suppress the production of inflammatory mediators, leading to reduced swelling, mucus production, and irritation of the nasal mucosa.

The prescribed dose of Mometasone Target is determined by the treating clinician based on the patient’s age, severity of symptoms, and specific indication. Patients should follow the exact dosing instructions provided on the prescription label.

Safety data for mometasone furoate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using this medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone Target contains mometasone furoate, a high‑potency corticosteroid with minimal systemic absorption when used nasally. Compared with lower‑potency agents such as fluticasone, it may achieve symptom control at lower daily doses, but the choice of therapy should be individualized by the prescriber.

Mometasone Target should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from excess moisture and direct sunlight to maintain its stability and efficacy.

Mometasone Target is administered as a nasal spray. The patient should prime the device if it is new, tilt the head slightly forward, insert the tip into one nostril, and spray while breathing in gently. The usual regimen involves one or two sprays per nostril once daily, unless otherwise directed by a clinician.

Serious risks, though rare, include nasal septal perforation, severe nosebleeds, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal cavity. Any unusual symptoms should be reported to a healthcare professional promptly.

Mometasone Target should be avoided in patients with known hypersensitivity to mometasone furoate or any component of the formulation, and in those with active, untreated nasal infections. Caution is also advised for individuals with uncontrolled glaucoma, cataracts, or systemic conditions that may be worsened by corticosteroids.